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Abstract: Introduction: There is still no consensus on the value of Manchester Acute Coronary Syndromes (MACS) deci-
sion rule in detecting acute coronary syndrome (ACS). Therefore, the purpose of the present systematic review
and meta-analyzes is to summarize the clinical evidence in the evaluation of the value of MACS in the diagno-
sis of ACS. Methods: A literature search was performed on the Medline, Embase, Scopus, and Web of Science
databases. Outcomes included acute myocardial infarction (AMI) and major adverse cardiac event (MACE).
Data were analyzed in the STATA 14.0 statistical program and the results were reported as summary receiver op-
erating characteristics (SROC), sensitivity, specificity, positive and negative likelihood ratio, and diagnostic odds
ratio with 95% confidence interval (95% CI). Results: Finally, 8 articles included in the meta-analysis. The area
under the SROC of MACS was excellent in rule out of AMI (AUC = 0.99, 95% CI: 0.97 to 0.99) and MACE (AUC
= 0.97, 95% CI: 0.95 to 0.98). The sensitivity and specificity of the troponin-only MACS / history electrocardio-
gram alone MACS (HE-MACS) in the rule out of AMI were 0.99 (95% CI: 0.98-0.99) and 0.22 (95% CI: 0.11-0.37),
respectively, and for the original MACS were in order 0.99 (95% CI: 0.98-0.99) and 0.26 (95% CI: 0.20-0.34). The
sensitivity and specificity of the troponin-only MACS / HE-MACS in the rule out of MACE were 0.94 (95% CI:
0.92-0.96) and 0.22 (95% CI: 0.12-0.39) compared to the 0.99 (95% CI: 0.98-0.99) and 0.27 (95% CI: 0.22-0.33) for
the original MACS. Conclusion: The findings of this study showed that original MACS, troponin-only MACS, and
HE-MACS are able to rule out AMI and MACE. However, further studies are needed in developing countries to
confirm its external validity.
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1. Introduction
A
cute coronary syndrome (ACS) is a leading cause of
mortality and disability worldwide. According to the
statistics, in 2017, about 18 million deaths from car-
diovascular disease have occurred in the world, which has
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increased by 21.1% over the past 10 years (1). This increase
in the burden of cardiovascular disease has led researchers
to seek solutions to reduce the incidence of ACS.
Early diagnosis of ACS is one of the most effective meth-
ods to reduce the burden of the disease (2). Currently, the
patient’ clinical examination, electrocardiography and serial
troponin are the standard ACS diagnostic method. A golden
standard for diagnosing ACS in emergency episodes is the
serial troponin test (3). However, the long-term approach
to diagnosing ACS (about 6-12 hours) is the most important
weakness of the current guidelines. In order to overcome this
problem, Body et al in 2014 provided the Manchester Acute
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Coronary Syndromes (MACS) decision rule to the diagnosis
of ACS (4). In subsequent studies, the diagnostic value of this
model was validated and modifications were made (5-9) (Ta-
ble 1). In recent years, troponin-only MACS and history and
electrocardiogram only MACS (HE-MACS) were introduced
to overcome MACS shortcoming. However, there is still no
comprehensive overview showing the performance of MACS
and its modifications in rule out of ACS. Therefore, the pur-
pose of the current systematic review and meta-analysis is
to summarize the clinical evidence in assessing the value of
MACS in the diagnosis of ACS.
2. Methods:
2.1. Search strategy
In the present meta-analysis using the keywords related
to Manchester Acute Coronary Syndromes score in com-
bination with Acute Coronary Syndrome, a search was
performed in the Medline, Embase, Scopus, and Web of
Science databases. The search was completed by the end of
October 2018. No language restrictions were applied. The
Searcy query for Medline (via PubMed) has been reported.
1- "Decision Support Techniques"[mh] OR "Manchester
Acute Coronary Syndromes"[tiab] OR "MACS prognos-
tic modes"[tiab] OR "MACS prognostic models"[tiab] OR
"MACS Rule"[tiab] OR "decision rule"[tiab] OR "Decision
Support Techniques"[tiab] OR "Decision Support Tech-
nique"[tiab] OR "Technique, Decision Support"[tiab] OR
"Techniques, Decision Support"[tiab] OR "Decision Support
Technics"[tiab] OR "Decision Support Technic"[tiab] OR
"Technic, Decision Support"[tiab] OR "Technics, Decision
Support"[tiab] OR "Decision Aids"[tiab] OR "Aid, Deci-
sion"[tiab] OR "Aids, Decision"[tiab] OR "Decision Aid"[tiab]
OR "Models, Decision Support"[tiab] OR "Decision Sup-
port Model"[tiab] OR "Decision Support Models"[tiab]
OR "Model, Decision Support"[tiab] OR "Decision Anal-
ysis"[tiab] OR "Analyses, Decision"[tiab] OR "Decision
Analyses"[tiab] OR "Analysis, Decision"[tiab] OR "Decision
Modeling"[tiab] OR "Modeling, Decision"[tiab] OR "Clinical
Prediction Rule"[tiab] OR "Clinical Prediction Rules"[tiab]
OR "Prediction Rule, Clinical"[tiab] OR "Prediction Rules,
Clinical"[tiab] OR "Rule, Clinical Prediction"[tiab] OR "Rules,
Clinical Prediction"[tiab]
2- "Acute Coronary Syndrome"[mh] OR "Myocardial Is-
chemia"[mh] OR "Angina Pectoris"[mh] OR "Angina,
Stable"[mh] OR "Angina, Unstable"[mh] OR "Coronary
Artery Disease"[mh] OR "Coronary Occlusion"[mh] OR
"Coronary Stenosis"[mh] OR "Coronary Thrombosis"[mh]
OR "Coronary Vasospasm"[mh] OR "Myocardial Infarc-
tion"[mh] OR "Anterior Wall Myocardial Infarction"[mh]
OR "Inferior Wall Myocardial Infarction"[mh] OR "Non-ST
Elevated Myocardial Infarction"[mh] OR "ST Elevation
Myocardial Infarction"[mh] OR "Acute Coronary Syn-
drome"[tiab] OR "Myocardial Ischemia"[tiab] OR "Angina
Pectoris"[tiab] OR "Angina, Stable"[tiab] OR "Angina, Unsta-
ble"[tiab] OR "Coronary Artery Disease"[tiab] OR "Coronary
Occlusion"[tiab] OR "Coronary Stenosis"[tiab] OR "Coro-
nary Thrombosis"[tiab] OR "Coronary Vasospasm"[tiab]
OR "Myocardial Infarction"[tiab] OR "Anterior Wall My-
ocardial Infarction"[tiab] OR "Inferior Wall Myocardial
Infarction"[tiab] OR "Non-ST Elevated Myocardial Infarc-
tion"[tiab] OR "ST Elevation Myocardial Infarction"[tiab]
OR "Acute Coronary Syndromes"[tiab] OR "Coronary Syn-
drome, Acute"[tiab] OR "Coronary Syndromes, Acute"[tiab]
OR "Syndrome, Acute Coronary"[tiab] OR "Syndromes,
Acute Coronary"[tiab] OR "Ischemia, Myocardial"[tiab]
OR "Ischemias, Myocardial"[tiab] OR "Myocardial Is-
chemias"[tiab] OR "Ischemic Heart Disease"[tiab] OR "Heart
Disease, Ischemic"[tiab] OR "Disease, Ischemic Heart"[tiab]
OR "Diseases, Ischemic Heart"[tiab] OR "Heart Diseases,
Ischemic"[tiab] OR "Ischemic Heart Diseases"[tiab] OR
"Anginas, Stable"[tiab] OR "Stable Angina"[tiab] OR "Sta-
ble Anginas"[tiab] OR "Chronic Stable Angina"[tiab] OR
"Angina, Chronic Stable"[tiab] OR "Anginas, Chronic Sta-
ble"[tiab] OR "Chronic Stable Anginas"[tiab] OR "Stable
Angina, Chronic"[tiab] OR "Stable Anginas, Chronic"[tiab]
OR "Angina Pectoris, Stable"[tiab] OR "Angina Pectori,
Stable"[tiab] OR "Pectori, Stable Angina"[tiab] OR "Pec-
toris, Stable Angina"[tiab] OR "Stable Angina Pectori"[tiab]
OR "Stable Angina Pectoris"[tiab] OR "Anginas, Unsta-
ble"[tiab] OR "Unstable Anginas"[tiab] OR "Angina Pectoris,
Unstable"[tiab] OR "Angina Pectori, Unstable"[tiab] OR
"Unstable Angina Pectori"[tiab] OR "Unstable Angina
Pectoris"[tiab] OR "Unstable Angina"[tiab] OR "Angina
at Rest"[tiab] OR "Angina, Preinfarction"[tiab] OR "Angi-
nas, Preinfarction"[tiab] OR "Preinfarction Angina"[tiab]
OR "Preinfarction Anginas"[tiab] OR "Myocardial Prein-
farction Syndrome"[tiab] OR "Myocardial Preinfarction
Syndromes"[tiab] OR "Preinfarction Syndrome, Myocar-
dial"[tiab] OR "Preinfarction Syndromes, Myocardial"[tiab]
OR "Syndrome, Myocardial Preinfarction"[tiab] OR "Syn-
dromes, Myocardial Preinfarction"[tiab] OR "Artery Disease,
Coronary"[tiab] OR "Artery Diseases, Coronary"[tiab] OR
"Coronary Artery Diseases"[tiab] OR "Disease, Coronary
Artery"[tiab] OR "Diseases, Coronary Artery"[tiab] OR
"Coronary Arteriosclerosis"[tiab] OR "Arterioscleroses,
Coronary"[tiab] OR "Coronary Arterioscleroses"[tiab] OR
"Atherosclerosis, Coronary"[tiab] OR "Atheroscleroses,
Coronary"[tiab] OR "Coronary Atheroscleroses"[tiab] OR
"Coronary Atherosclerosis"[tiab] OR "Arteriosclerosis,
Coronary"[tiab] OR "Coronary Occlusions"[tiab] OR "Occlu-
sion, Coronary"[tiab] OR "Occlusions, Coronary"[tiab] OR
"Stenoses, Coronary"[tiab] OR "Stenosis, Coronary"[tiab]
OR "Coronary Artery Stenosis"[tiab] OR "Artery Stenoses,
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Figure 1: Flow diagram of present meta-analysis.
Figure 2: Publication bias in assessment of value of Manchester
Acute Coronary Syndromes score in prediction of acute myocardial
infarction (A) and major adverse cardiac events (B).
Coronary"[tiab] OR "Artery Stenosis, Coronary"[tiab] OR
"Coronary Artery Stenoses"[tiab] OR "Stenoses, Coronary
Artery"[tiab] OR "Stenosis, Coronary Artery"[tiab] OR "Coro-
nary Stenoses"[tiab] OR "Infarction, Myocardial"[tiab] OR
"Infarctions, Myocardial"[tiab] OR "Myocardial Infarc-
tions"[tiab] OR "Cardiovascular Stroke"[tiab] OR "Cardio-
vascular Strokes"[tiab] OR "Stroke, Cardiovascular"[tiab]
OR "Strokes, Cardiovascular"[tiab] OR "Heart Attack"[tiab]
OR "Heart Attacks"[tiab] OR "Myocardial Infarct"[tiab] OR
"Infarct, Myocardial"[tiab] OR "Infarcts, Myocardial"[tiab]
OR "Myocardial Infarcts"[tiab]
3- #1 and #2
Figure 3: Summary receiver operator characteristics curve of
Manchester Acute Coronary Syndromes score in prediction of acute
myocardial infarction (A) and major adverse cardiac events (B).
2.2. Selection criteria
Inclusion criteria included relevant studies in the assessment
of MACS in rule out of acute myocardial infarction (AMI)
and major acute cardiac event (MACE). Exclusion criteria in-
cluded the lack of the required data after contact with the au-
thors, duplicate articles, and reviews.
2.3. Data synthases and quality control
The method of summarizing and collecting data has been re-
ported by previous systematic reviews (10-25). In summary,
two independent reviewers screened the titles and abstracts
as well as full text of the articles and selected relevant studies.
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Table 1: Manchester Acute Coronary Syndromes score (MACS)
Original MACS Troponin-only MACS HE-MACS
1- Heart-type fatty acid binding protein
p
—– —–














8- Pain radiating to right arm or shoulder
p p p
9- Current tobacco smoker —– —–
p
10- Age —– —–
p
11- Male sex —– —–
p
Table 2: Characteristics of included studies
Author; Age Sample Male Type Timing of Sampling Type of Outcome Follow-up
year; country group size gender of study blood sample MACS (day)
Alghamdi; Adult 1902 1160 Derivation-validation 0 Consecutive HE-MACS MACE 30
2018; UK cohort
Body; Adult 1161 699 Derivation-validation 0 Consecutive Original MACS AMI; MACE 30
2014; UK cohort and Tro-only
Body; Adult 456 264 Validation cohort 0 Consecutive Original MACS AMI; MACE 30
2015; UK
Body; Adult 1577 1304 Validation cohort 0 Consecutive Tro-only AMI; MACE 30
2016; UK
Body; Adult 131 79 Validation trial 0 Consecutive Original MACS MACE 30-90
2017; UK
Carlton; Adult 782 466 Validation cohort 0 Consecutive Original MACS AMI; MACE 30
2016; UK




Va Den Berg; Adult 405 233 Validation cohort 0 Consecutive Original MACS AMI; MACE 30
2018; UK and Tro-only
AMI: Acute myocardial infarction; h-FABP: heart type fatty acid binding protein; HE-MACS: History and electrocardiogram-only
Manchester Acute Coronary Syndromes score; MACE: Major adverse cardiac events; MACS: Manchester Acute Coronary Syndromes
score; Tro-only: Troponin-only.
Any disagreement was resolved by discussion with the third
reviewer.
The collected data included the name of the first author,
the year of study, the number of patients (normal, AMI, and
MACE), the type of study (derivation and validation), the
type of MACS (the original MACS, the troponin-only MACs,
and HE-MACS), the assessed outcome (AMI and MACE)
and follow-up duration. MACE included all-cause mortal-
ity, AMI, and urgent coronary revascularization. Quality as-
sessment of the articles was evaluated using the proposed
method of Quality Assessment of Diagnostic Accuracy Stud-
ies 2 (QUADAS-2) guideline (26).
2.4. Statistical analysis
All analyzes were performed in the STATA 14.0 statistical pro-
gram. Using the values reported in the relevant studies, we
calculated true positive, true negative, false positive and false
negative. Data were analyzed by “midas” command and the
results were reported as a summary receiver operating char-
acteristic (SROC) curve, sensitivity, specificity, positive and
negative likelihood ratio, and diagnostic odds ratio with 95%
confidence interval (95% CI). The publication bias was evalu-
ated using Deeks’ funnel plot asymmetry test. In all analyzes
p <0.05 was considered a significant level.
3. Results:
3.1. Characteristics
The search led to the achievement of 3175 non-repetitive
records. After the initial screening, 21 articles were studied
in detail, and finally, eight papers arrived at the quantita-
tive analysis (4-7, 9, 27-29). Figure 1 illustrates the flow di-
agram of the present meta-analysis. These eight articles con-
tained 33 separate experiments. There were six cohort arti-
This open-access article distributed under the terms of the Creative Commons Attribution NonCommercial 3.0 License (CC BY-NC 3.0).
Downloaded from: www.jemerg.com
5 Emergency. 2018; 6 (1): e61
Table 3: Quality assessment of included articles
Author













© © © © © © ©
Body; 2014 © © © © © © ©
Body; 2015 © © © © © © ©
Body; 2016 © © © © © © ©
Body; 2017 © © © © © © ©
Carlton; 2016 © © © © © © ©
Greenslade;
2017
© © © © § © ©
Va Den Berg;
2018
? © © © ? © ©
©: Low Risk;§: High Risk; ?: Unclear Risk
Table 4: Performance of MACS in detection of cardiac events among subgroups
Subgroup Number of AUC Sensitivity Specificity PLR NLR DOR
experiments (95% CI) (95% CI) (95% CI) (95% CI) (95% CI) (95% CI)
AMI
Overall 15 0.99 (0.97-0.99) 0.99 (0.98-0.99) 0.24 (0.18-0.32) 1.3 (1.2-1.4) 0.04 (0.03-0.08) 29.0 (16.0-55.0)
Type of MACS
Original MACS 8 0.99 (0.97-0.99) 0.99 (0.98-0.99) 0.26 (0.20-0.34) 1.3 (1.1-1.5) 0.02 (0.008-0.07) 31.0 (14.0-68.0)
Tro-only and
HE-MACS
7 0.99 (0.97-0.99) 0.99 (0.98-0.99) 0.22 (0.11-0.37) 1.5 (1.3-1.7) 0.03 (0.01-0.07) 51.0 (16.0-162.0)
Type of study
Validation 4 0.99 (0.98-1.0) 0.99 (0.98-1.0) 0.26 (0.12-0.48) 1.3 (1.0-1.7) 0.03 (0.01-0.10) 42.0 (11.0-163.0)
Derivation 11 0.99 (0.97-0.99) 0.99 (0.98-0.99) 0.24 (0.17-0.32) 1.3 (1.2-1.4) 0.05 (0.03-0.10) 25.0 (13.0-51.0)
MACE
Overall 18 0.97 (0.95-0.98) 0.99 (0.98-0.99) 0.25 (0.19-0.32) 1.3 (1.2-1.4) 0.05 (0.03-0.09) 25.0 (13.0-43.0)
Type of MACS
Original MACS 11 0.98 (0.97-0.99) 0.99 (0.98-0.99) 0.27 (0.22-0.33) 1.4 (1.3-1.5) 0.05 (0.03-0.09) 27.0 (14.0-53.0)
Tro-only and
HE-MACS
7 0.94 (0.92-0.96) 0.99 (0.97-1.0) 0.22 (0.12-0.39) 1.3 (1.1-1.5) 0.05 (0.02-0.12) 27.0 (10.0-71.0)
Type of study
Validation 4 0.98 (0.96-0.99) 0.99 (0.98-1.0) 0.27 (0.12-0.49) 1.4 (1.0-1.8) 0.03 (0.01-0.08) 48.0 (16.0-146.0)
Derivation 14 0.97 (0.95-0.99) 0.98 (0.97-0.99) 0.25 (0.19-0.32) 1.3 (1.2-1.4) 0.06 (0.04-0.10) 20.0 (12.0-33.0)
AMI: Acute myocardial infarction; CI: Confidence interval; AUC: Area under the curve; DOR: Diagnostic odds ratio; HE-MACS: History
and electrocardiogram-only MACS; MACE: Major adverse cardiac events; MACS: Manchester Acute Coronary Syndromes score;
NLR: Negative likelihood ratio; PLR: Positive likelihood ratio; Tro-only: Troponin-only
cles and 2 of them were observational trials. Data from 7658
patients were analyzed. Of these, there were 1203 AMI and
1504 MACE. 64.29% of patients were male. Two studies were
derivation-validation and other was validation. Table 2 pro-
vides a summary of related articles.
3.2. Quality control of articles and risk of bias
The quality assessment showed that the applicability of pa-
tient selection was high risk and unclear in two studies. In
addition, in one study, the risk of bias in patient selection
was unclear. In other cases, the risk of bias were low. Table
3 shows the quality status of the articles. Deeks funnel plot
asymmetry test showed that there was no publication bias in
the evaluation of the MACS in the rule out of AMI and MACE
(Figure 2).
3.3. The value of MACS in rule out of AMI
Data from seven studies (15 separate experiments) included
in this section. The analysis showed that the area under the
SROC curve of MACS in the rule out of AMI was excellent
(AUC = 0.99, 95% CI: 0.97 to 0.99) (Figure 3). The sensitiv-
ity and specificity of the MACS decision aid in the diagnosis
of AMI were 0.99 (95% CI: 0.98-0.99) and 0.24 (95% CI: 0.18-
0.32), respectively. In addition, DOR of this rule out criteria
was 29.0 (95% CI: 16.0-55.0) (Figure 4 and Table 4). The sen-
sitivity and specificity of troponin-only MACS / HE-MACS in
the diagnosis of AMI was 0.99 (95% CI: 0.98-0.99) and 0.22
(95% CI: 0.11-0.37), respectively. These values for the original
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Figure 4: Performance of Manchester Acute Coronary Syndromes
score in prediction of acute myocardial infarction and major adverse
cardiac events. A) Sensitivity and specificity; B) Diagnostic score and
diagnostic odds ratio.
MACS were 0.99 (95% CI: 0.98-0.99) and 0.26 (95% CI: 0.20-
0.34), respectively. In thesensitivity (0.99 vs. 0.99) and speci-
ficity (0.26 vs. 0.24) of MACS there was no differencebetween
validation and derivation studies (Table 4).
3.4. Diagnostic value of MACS in MACE detection
Data from eight studies (18 separate experiments) were in-
cluded in this section. The analysis showed that the area un-
der the SROC curve of MACS in the rule out of MACE was ex-
cellent (AUC = 0.97, 95% CI: 0.95 to 0.98) (Figure 3). The sen-
sitivity, specificity and DOR of the MACS rule in prediction of
MACE were 0.99 (95% CI: 0.98-0.99) and 0.25 (95% CI: 0.19-
0.32), and 25.0 (95% CI: 13.0-43.0), respectively (Figure 5 and
Table 4). The sensitivity and specificity of the troponin-only
MACS / HE-MACS in the rule out of MACE was 0.94 (95% CI:
0.92-0.96) and 0.22 (95% CI: 0.12-0.39), respectively. These
values for the original MACS were 0.99 (95% CI: 0.98-0.99)
and 0.27 (95% CI: 0.22-0.33) respectively. The sensitivity (0.98
vs. 0.97) and specificity (0.27 vs. 0.25) of MACS were not
different in the MACE prediction between the validation and
Figure 5: Performance of Manchester Acute Coronary Syndromes
score in prediction of major adverse cardiac events. A) Sensitivity
and specificity; B) Diagnostic score and diagnostic odds ratio.
derivation studies (Table 4).
4. Discussion:
The findings of this study showed that the MACS value is
good in the screening of AMI and MACE. It was also found
that the value of troponin-only / HE-MACS is similar to the
original MACS. Since troponin-only MACS and HE-MACS
have fewer variables and don’t need to evaluate the heart-
type fatty acid binding protein, it seems that the use of
troponin-only / HE-MACS is better than the original MACS.
The MACS sensitivity to rule out of ACS is very high, but its
specificity is low. Therefore, MACS is a good screening tool
for AMI diagnosis and MACE prediction. In line with the
present review article, Reynard et al. by reviewing five stud-
iesconcluded that MACS is a good model for rule out of ACS
(26). In the present study, 8 articles included in the meta-
analysis. Although data from 7658 patients were analyzed,
7 studies were conducted by a team in the UK (4-7, 9, 27,
28). Only one study in Australia and New Zealand performed,
that only 405 patients were examined (29). Therefore, exter-
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nal validation of MACS in other communities is also required
to ensure it is generalized.
The findings of this study indicate that the performance of
troponin-only MACS or HE-MACS in rule out of ACS is not
different from the original MACS. One of the main disadvan-
tages of the original MACS is the need to evaluate the heart-
type fatty acid binding protein (h-FABP), while in the other
two models, it is not necessary to measure h-FABP . The value
of the troponin-only MACS in rule out of ACS was evaluated
in four studies, while the value of HE-MACS was examined
only in one study. Since the HE-MACS method does not re-
quire measurement of high sensitivity troponin and h-FABP,
so if the screening value of HE-MACS is confirmed, it will be
easier to use for rule out the ACS. Further studies are needed
to achieve this goal.
5. Conclusion
The findings of this study showed that the original MACS,
troponin-only MACS, and HE-MACS are capable to rule out
AMI and MACE. However, further studies are needed in de-
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